Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$72.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Harel Gadot
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 43
- Beta
- 1.05
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 3.83
Financials
Revenue
$72.0KNet Income
$-5.84M-458.2%EBITDA
$-6.47M-499.1%Free Cash Flow
$-5.52M-123.3%EPS (diluted)
$-0.09-102.8%Shares Outstanding (diluted)
67.16M+483.7%Operating Expenses
$1.47MCash & Debt
$61.83MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-13.14M | $-0.29 |
| 2024 | $0.00 | $-11.44M | $-0.73 |
| 2023 | $0.00 | $-10.74M | $-1.05 |
| 2022 | $0.00 | $-13.17M | $-1.81 |
| 2021 | $0.00 | $-11.31M | $-1.59 |
| 2020 | $0.00 | $-9.17M | $-1.29 |
| 2019 | $0.00 | $-7.25M | $-1.70 |
| 2018 | $0.00 | $-7.26M | $-0.81 |
| 2017 | $0.00 | $-7.59M | $-0.85 |
| 2016 | $0.00 | $-9.66M | $-10.14 |
| 2015 | $117.0K | $-36.41M | $-12.58 |
| 2014 | $1.01M | $-32.74M | $-858.60 |
| 2013 | $1.20M | $-26.44M | $-986.43 |
| 2012 | $1.37M | $-28.49M | $-1603.80 |
Valuation
MBOThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·6d ago·Negative
…RTY, while utilization of the LIBERTY System rose 44% compared to the second quarter HINGHAM, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today announced that it has filed its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2026, with the Securities and Exchange Commission.
View source ↗ - Newszacks.com·9d ago·Negative
Microbot Medical Inc. (MBOT) Reports Q3 Loss, Misses Revenue Estimates Microbot Medical Inc. (MBOT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.07 per share a year ago.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System ELMNT IR also became the first account on the West Coast, marking a geographic expansion which aligns with the Company's Full Market Release strategy. The Company believes the OBLs represent a rapidly growing healthcare segment and opportunity as many endovascular procedures are being done outside traditional hospital settings and Ambulatory Surgery Centers.
View source ↗ - Newsglobenewswire.com·30d ago·Neutral
…ce to Engage with Decision-makers as it Continues to Expand Presence Across the U.S. HINGHAM, Mass., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today announced that key executives and members of the Company's commercial team will be attending the SIR EDGE 2026 conference in Louisville, Kentucky, providing an opportunity for the Company to engage with prospective customers.
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY® Endovascular Robotic System Throughout Israel Microbot Medical is Executing its International Markets Strategy by Engaging with Distributors in Developed Markets to Prepare for Potential Future Market Entry Outside of the U.S. HINGHAM, Mass.
View source ↗ - Newsglobenewswire.com·58d ago·Neutral
Microbot Medical® Highlights Growth Strategy Service Unavailable Service Unavailable HTTP Error 503. The service is unavailable.
View source ↗ - Newszacks.com·103d ago·Negative
Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates Microbot Medical Inc. (MBOT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.1 per share a year ago.
View source ↗
Earnings
Thu, Mar 25(in 4 months)
Consensus estimate $-0.08 per share
Typical surprise -7.1% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Nov 13$-0.09 vs $-0.08miss
- Tue, Aug 11$-0.08 vs $-0.07miss
- Wed, May 13$-0.05 vs $-0.08beat
- Thu, Mar 26$-0.04 vs $-0.06beat
- Wed, Nov 12$-0.07 vs $-0.06miss
- Tue, Aug 12$-0.10 vs $-0.08miss
Estimates and results for MBOT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MBOT officers and directors.
- Bought
- $210k
- Sold
- $5.7m
6 trades
14 trades
- Bornstein Yosephsold
- Bornstein Yosephsold
- Bornstein Yosephsold
- Bornstein Yosephsold
- Bornstein Yosephsold
- Bornstein Yosephsold
- Bornstein Yosephsold
- Gadot Harelsold
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MBOT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
